Jun 22 2012
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the
launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25
mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of
Symbyax®.
Symbyax® is marketed by Lilly USA and approved for the acute
treatment of treatment-resistant depression and bipolar I depression in
adults. The brand product had annual sales of approximately $82 million
in the United States, based on IMS sales data.
Source: Teva Pharmaceutical Industries Ltd.
Study identifies link between oral and gut microbiomes and depression